Krystal Biotech Q3 VYJUVEK revenue $97.8M; label expanded, EU/Japan launches

Krystal Biotech, Inc.

2025-Q3 EPS reported $5.14 revenue$282,025,000

Q3 net product revenue $97.8M (vs $83.8M YoY); net income $79.4M ($2.74 basic EPS); cash $864.2M.
FDA expanded VYJUVEK label to include DEB patients from birth and allow at-home application.
VYJUVEK launched in Germany (Aug), France (Oct), and Japan (Oct); >615 US reimbursement approvals.
FDA granted platform technology designation to HSV-1 vector used in KB801 and other programs.
CF interim data (KB407) expected Q4; KB111 IND cleared for Hailey-Hailey disease; intratumoral KB707 enrollment paused.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.